ASSESSMENT OF CIRCULATING miRNA LEVELS IN BREAST CANCER PATIENTS DEPENDING ON CLINICAL CHARACTERISTICS AND CHEMOTHERAPY
DOI:
https://doi.org/10.15407/exp-oncology.2023.04.451Keywords:
breast cancer, miRNA, blood plasma, chemotherapyAbstract
Background. Breast cancer (BC) stands out as the most prevalent cancer in women. The levels of miRNA expression before and after chemotherapy are considered a potential indicator for the prognosis of the disease. Aim. To study blood plasma miRNA levels in BC patients and to assess their correlation with the menopausal status, disease stage, and molecular BC subtype. Materials and Methods. Blood plasma levels of 6 miRNAs (miRNA-25, miRNA-27, miRNA-155, miRNA-200, miRNA-335, and miRNA-497) were studied in 70 BC patients and 18 healthy individuals using RT-PCR. Results. miRNA-25, miRNA-335, and miRNA-497 levels were significantly higher in BC patients, while a tendency toward a decrease in the miRNA-27 and miRNA-335 levels in premenopausal patients and high miRNA-27 levels in menopausal patients was established. After neoadjuvant chemotherapy, a decrease in the miRNA-25 and miRNA-335 levels was registered. Conclusions. The results indicated that miRNA-25, miRNA-27, miRNA-335, and miRNA-497 deserve attention as markers for assessing the efficacy of treatment of BC patients.
References
Singh S, Saini H, Sharma A, et al. Breast cancer: miRNAs monitoring chemoresistance and systemic therapy. Front Oncol. 2023;13:1155254. https://doi.org/10.3389/fonc.2023.1155254.
Walsh EM, Smith KL, Stearns V. Management of hormone receptor-positive, HER2-negative early breast cancer.
Semin Oncol. 2020;47(4):187-200. https://doi.org/10.1053/j.seminoncol.2020.05.010.
Wu X, Ding M, Lin J. Three-microRNA expression signature predicts survival in triple-negative breast cancer. Oncol Lett. 2020;19(1):301-308. https://doi.org/10.3892/ol.2019.11118.
Kravets О, Burtyn, O, Borikun T, et al. The study of prognostic value of microRNAs (miR-10b and -155) and CD- KN2A/P16INK4A in oral squamous cell carcinoma. Exp Oncol. 2023;45(2):187-194. https://doi.org/10.15407/exp-oncology.2023.02.187
Garrido-Palacios A, Rojas Carvajal AM, Núñez-Negrillo AM, et al. MicroRNA dysregulation in early breast cancer diagnosis: a systematic review and meta-analysis. Int J Mol Sci. 2023;24(9):8270. https://doi.org/10.3390/ ijms24098270
Hu Z, Dong J, Wang LE, et al. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis. 2012;33(4):828-834. https://doi.org/10.1093/carcin/bgs030
Sun H, Dai J, Chen M, et al. miR-139-5p was identified as biomarker of different molecular subtypes of breast carcinoma. Front Oncol. 2022;12:857714. https://doi.org/10.3389/fonc.2022.857714
Krishnan K, Steptoe AL, Martin HC, et al. miR-139-5p is a regulator of metastatic pathways in breast cancer. RNA. 2013;19(12):1767-1780. https://doi.org/10.1261/rna.042143.113
Abbas MA, El Sayed IET, Kamel Abdu-Allah AM, et al. Expression of MiRNA-29b and MiRNA-31 and their diagnostic and prognostic values in Egyptian females with breast cancer. Noncoding RNA Res. 2022;7(4):248-257. https://doi.org/10.1016/j.ncrna.2022.09.003
Peña-Chilet M, Martínez MT, Pérez-Fidalgo JA, et al. MicroRNA profile in very young women with breast cancer. BMC Cancer. 2014;14:529. https://doi.org/10.1186/1471-2407-14-529
Zhang J, Ma L. MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev. 2012;31(3-4):653-662. https://doi.org/10.1007/s10555-012-9368-6
Gomarasca M, Maroni P, Banfi G, et al. microRNAs in the antitumor immune response and in bone metastasis of breast cancer: from biological mechanisms to therapeutics. Int J Mol Sci. 2020;21(8):2805. https://doi.org/10.3390/ijms21082805
Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 2015;5(10):1122-1143. https://doi.org/10.7150/thno.11543
Anwar S, Tanjung D, Fitria MS, et al. Dynamic changes of circulating miR-155 expression and the potential application as a non-invasive biomarker in breast cancer. Asian Pac J Cancer Prev. 2020;21(2):491. https://doi.org/10.31557/APJCP.2020.21.2.491
Fischer C, Deutsch T, Feisst M, et al. Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer. Arch Gynecol Obstet. 2022;306(3):875-885. https://doi.org/10.1007/s00404-022- 06442-2
Ali Ahmed E, Abd El-Basit S, Mohamed M, Swellam M. Clinical role of MiRNA 29a and MiRNA 335 on breast cancer management: their relevance to MMP2 protein level. Arch Physiol Biochem. 2022;128(4):1058-1065. https://doi.org/10.1080/13813455.2020.1749085
Nashtahosseini Z, Sadeghi F. Changes in expression of miRNA-320a and miRNA-497-5p in early stage of breast cancer. Iranian Red Cresc Med J. 2021;23(6):1-8. https://doi.org/10.32592/ircmj.2021.23.6.444
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
